A Trial of Folate With B12 in Patients With Schizophrenia With Residual Symptoms in Ethiopia
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The investigators propose to conduct a randomized Sequential Parallel Design for Double-Blind
Phase fixed dose, 4-month trial of folate plus B12 as add-on therapy in 200 Ethiopian
subjects with schizophrenia with stable residual positive or negative symptoms.
Phase:
Phase 4
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Addis Ababa University Amanuel Mental Hospital, Addis Ababa, Ethiopia